Leucine Rich Bio Expands to GCC with Dubai Operations

Leucine Rich Bio, South Asia’s first and only dedicated microbiome company, has officially launched its regional arm, Leucine Rich Bio Middle East FZCO in Dubai, marking a strategic expansion to serve the fast-growing microbiome wellness market in the GCC and MENA region.

With over a decade of microbiome leadership and one of Asia’s most extensive microbiomic data repositories, Leucine Rich Bio brings its flagship solutions—BugSpeaks microbiome diagnostics and Rychbiome wellness formulations—to the Middle East.

This Dubai hub will drive collaborations with healthcare providers, research institutions, and wellness ecosystems, offering localized precision wellness and preventive care solutions rooted in microbiome science.

Kumar Sankaran, CEO of Leucine Rich Bio, shared, “The Middle East is rapidly emerging as a global healthcare innovation hub. Establishing our presence in Dubai positions us to deliver advanced microbiome testing and co-develop solutions tailored to regional health needs with our local partners.”

Hidayath Shariff, Managing Partner – Dubai, added, “Dubai is an ideal launchpad for our Middle East operations. The region's dedication to healthcare innovation aligns with our vision of demystifying microbiome science and integrating it into daily wellness.”

Leucine Rich Bio Middle East FZCO will deliver comprehensive microbiome solutions in the region:

• BugSpeaks : South Asia’s first microbiome test offering insights into immunity, metabolism, and mental-health-related conditions. It uses DNA sequencing and proprietary analytics to provide personalized nutrition and lifestyle guidance; this test already holds ISO 9001, ISO 17025, NABH, and NABL certifications. The tests include the gut microbiome profiling, skin microbiome profiling, vaginal and oral microbiome profiling

• Research based solutions : Microbiome research based projects that entail complex microbiome analysis and solutions

This expansion also enables future research partnerships targeting therapeutic innovations specific to the regional microbiome landscape.